Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
NCT03237026 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 360
Last updated 2026-01-20
Summary
The study aims to identify potential urine marker metabolites as predictive or prognostic markers for treatment outcomes in patients with prostate cancer.
Conditions
Interventions
- OTHER
-
No intervention required
No intervention required
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Principal Investigators
-
Yeong-Shiau Pu, MD PhD · Department of Urology, National Taiwan University Hospital
Eligibility
- Min Age
- 30 Years
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-10-11
- Primary Completion
- 2027-01-15
- Completion
- 2031-07-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer
NCT00045331 ·Status: COMPLETED ·Phase: NA
-
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy
NCT00373035 ·Status: COMPLETED
-
Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level
NCT03488706 ·Status: UNKNOWN
-
Early Detection of Prostate Cancer
NCT04556916 ·Status: RECRUITING ·Phase: NA
-
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
NCT02594202 ·Status: RECRUITING
-
Circulating Tumor DNA in High Risk Localized Prostate Cancer
NCT07222436 ·Status: RECRUITING
-
A Diagnostic Prediction Model for Prostate Cancer in Patients With PI-RADS Score 3
NCT06507462 ·Status: COMPLETED
-
Non-Invasive Biomarkers in Prostate Cancer Disease Management
NCT06144619 ·Status: SUSPENDED
-
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
NCT04067713 ·Status: ACTIVE_NOT_RECRUITING
-
Focal Therapy for Localized Prostate Cancer
NCT03970863 ·Status: WITHDRAWN
-
Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique
NCT02940977 ·Status: UNKNOWN
-
PRostate Cancer Plasma Integrative Multi-modal Evaluation
NCT06981377 ·Status: RECRUITING
-
Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer
NCT03927287 ·Status: COMPLETED
-
PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma
NCT00427817 ·Status: COMPLETED
-
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
NCT04964271 ·Status: ACTIVE_NOT_RECRUITING
-
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer
NCT06600802 ·Status: RECRUITING ·Phase: NA
-
Prostate Cancer Screening: a Pilot Study
NCT06238661 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
NCT00898274 ·Status: COMPLETED
-
Precision-Based Genomics in Prostate Cancer
NCT04706663 ·Status: RECRUITING
-
Predictive Nomogram of CRPC
NCT03177551 ·Status: UNKNOWN
-
Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor
NCT04825002 ·Status: UNKNOWN ·Phase: NA
-
Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient
NCT05422105 ·Status: UNKNOWN
-
Genetic Biomarker Discovery for Metastatic Prostate Cancer
NCT03228810 ·Status: COMPLETED
-
To Identify Potential New Urine Markers for the Screening of Prostate Cancer
NCT03914391 ·Status: RECRUITING
-
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand
NCT04266392 ·Status: COMPLETED ·Phase: EARLY_PHASE1